• Males \> 18 years who have gone through external or internal, high dose rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence.

• Prostate volume less than 50 cm3 defined by transrectal ultrasound

• Subject not eligible for surgery or curative radiotherapy

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

• Expected survival ≥ 8 months

• Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3

• Adequate renal function as defined by creatinine ≤ 1.5 mg /dl

• Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate-oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal

• Signed Informed Consent

• Subjects \> 18 years who have gone through external or internal, high dose-rate (brachy) radiation therapy for localized prostate cancer with histopathologically verified local recurrence.

• Treatment target volume less than 50 cm3.

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Expected survival ≥ 12 months.

• Sufficient bone marrow reserve as indicated by; granulocyte count ≥ 1500/mm3, platelet count ≥ 100,000/mm3.

• Adequate renal function as defined by creatinine ≤ 1.5 mg /dl.

• Adequate hepatic function, based on a total bilirubin ≤ 1.5 mg/dl, serum glutamate- oxaloacetate transaminase (SGOT) ≤ 3 times the upper limit of normal, and alanine transaminase (ALT) ≤ 3 times the upper limit of normal.

• Signed Informed Consent.